Headlines

The Indirect Impacts of the Inflation Reduction Act on Pharmaceutical Pipeline and Portfolio Strategy

The Indirect Impacts of the Inflation Reduction Act on Pharmaceutical Pipeline and Portfolio Strategy

In August 2022, President Joe Biden signed into law the Inflation Reduction Act (IRA) aimed at reforming federal spending toward lowering healthcare costs, among numerous other aims. Although the future of this legislation is under question, as will be explored toward the end of this discussion, the enactment of the IRA marks the start of an inevitable waterfall of bipartisan policy action and drug pricing reform, which industry stakeholders will need to monitor.

At a little more than one year since the passage of this act, it is likely that every drug manufacturer understands the tenets of the IRA and its direct implications for cross-functional decision making. However, this brief publication seeks to build on that understanding, by illustrating the indirect implications of the IRA that manufacturers will need to consider as part of their new product planning and portfolio strategy.

The Indirect Impacts

I acknowledge and agree to the use of my contact information to receive messages about offerings by Questex, its brands, affiliates and/or third-party partners, consistent with Questex Privacy Policy